Short answer
Pfizer Inc (PFE) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Pfizer reported second-quarter 2026 financial results on August 4, 2026.
Pfizer Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Pfizer reported second-quarter 2026 financial results on August 4, 2026
- Detailed revenue, earnings and outlook figures are contained in Exhibit 99
- Results provide the latest quarterly update on Pfizer’s operating performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $15.034B, up 3%; operational growth 1%, excluding Comirnaty and Paxlovid growth reached 5%
- Launched and acquired products grew 18% operationally, led by Eliquis 19%, Padcev 23%, Vyndaqel 8%, and Lorbrena 37%
- Adjusted EPS $0.77; reported loss $(0.04) reflects $4.3B of non-cash intangible impairments
- 2026 revenue guidance raised to $60.5B–$62.5B, midpoint up $500M; COVID revenue expectation reduced to approximately $4B
- Additional savings targeted: $2.5B through 2029, requiring approximately $6.0B in one-time costs across productivity and manufacturing programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pfizer Inc 8-K filings
Get the next PFE 8-K as it lands
Follow PFE for push alerts, or ask the research agent what this filing means.